Erica Melkonian, DO
Family Medicine · Golden, CONPI 1558984641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Amgen at 47.6% of the total. Reporting peaked in 2022 at $421 and has fallen 56.7% since, to $182 in 2023.
Across 16 payments — averaging $51.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$391
- Novo Nordisk$125
- Grifols USA, LLC$124
- AbbVie$46
- Biohaven Pharmaceuticals, Inc.$43
- Organon$23
- plus $68 from 4 others
What the payments were for
- Food & beverage$821100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 4 | $391 |
| Novo Nordisk | 1 | $125 |
| Grifols USA, LLC | 1 | $124 |
| AbbVie | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Organon | 1 | $23 |
| Myovant Sciences Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Merck | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$244
- Wegovy$125
- Prolastin-C Liquid$124
- AIMOVIG$123
How this compares
$821 in reported general payments places this provider in the 80th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,622 |
| XareltoRivaroxaban | 14 | $12,085 |
| Levothyroxine Sodium | 57 | $509 |
| Omeprazole | 22 | $489 |
| Duloxetine Hcl | 12 | $462 |
| Rosuvastatin Calcium | 37 | $291 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $262 |
| Chlorthalidone | 29 | $258 |
| Gabapentin | 26 | $241 |
| Lisinopril | 26 | $234 |
| Amlodipine Besylate | 39 | $211 |
| Fluticasone Propionate | 19 | $182 |
| Trazodone Hcl | 16 | $170 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $161 |
| Metformin Hcl ErMetformin Hcl | 17 | $155 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Golden
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.